New work in JAMA Neurology by CP3's Alvaro San-Juan-Rodriguez, PharmD, Bernie Good, MD, MPH, Inma Hernandez, PharmD, PhD, and others shows that patient out-of-pocket costs for self-administered disease-modifying therapies for multiple sclerosis increased more than 7-fold over ten years. "We discovered that actual price increases do get passed down to patients, and that can negatively affect access," Dr. Hernandez told MD Magazine. Other news outlets that have reported on these findings include Pain News Network, Inside Health Policy, BioPharma Dive, and Pharmalot.